Li Hao, Wang Manzhou, Chen Pengfei, Li Fangzheng, Kuang Donglin, Han Xinwei, Ren Jianzhuang, Duan Xuhua
Department of Interventional Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, People's Republic of China.
Onco Targets Ther. 2021 Aug 31;14:4659-4670. doi: 10.2147/OTT.S297523. eCollection 2021.
The present study aimed to assess the prevalence of vascular lake (VL), its associated factors and correlation with prognosis in hepatocellular carcinoma (HCC) patients treated with drug-eluting bead transarterial chemoembolization (DEB-TACE).
A total of 286 primary HCC patients (with 384 treated nodules) receiving DEB-TACE treatment were recruited, and their clinical characteristics were documented. The occurrence of VL was recorded, and treatment responses were assessed according to the modified response evaluation criteria in solid tumor (mRECIST).In terms of treatment response, the total response status (including CR, PR, SD and PD), objective response rate (ORR) and disease control rate (DCR) were elevated in VL patients compared to non-VL patients as well as in VL nodules compared to non-VL nodules. Liver function indexes and adverse events were assessed. Progression-free survival (PFS) and overall survival (OS) were evaluated with the last follow-up date of March 2020.
The patient-based and nodule-based VL occurrence rates were 17.1% and 16.4%, respectively. Larger tumor size, pseudocapsules and smaller bead size were independently associated with VL occurrence. PFS and OS were more prolonged in VL patients than in non-VL patients, and VL independently correlated with better PFS and OS. For liver function, the liver function indexes before and after DEB-TACE were of no difference between VL patients and non-VL patients. Additionally, the incidences of adverse events were similar between VL patients and non-VL patients.
VL occurs in 17.1% of HCC patients treated with DEB-TACE, and it is correlated with larger tumor size, pseudocapsule, smaller bead size, more favorable treatment response and better survival.
本研究旨在评估接受载药微球经动脉化疗栓塞术（DEB-TACE）治疗的肝细胞癌（HCC）患者中血管湖（VL）的发生率、相关因素及其与预后的相关性。
共纳入286例接受DEB-TACE治疗的原发性HCC患者（384个治疗结节），记录其临床特征。记录VL的发生情况，并根据实体瘤改良反应评估标准（mRECIST）评估治疗反应。在治疗反应方面，与非VL患者相比，VL患者的总反应状态（包括CR、PR、SD和PD）、客观反应率（ORR）和疾病控制率（DCR）均有所提高，与非VL结节相比，VL结节的上述指标也有所提高。评估肝功能指标和不良事件。采用2020年3月的最后随访日期评估无进展生存期（PFS）和总生存期（OS）。
基于患者和基于结节的VL发生率分别为17.1%和16.4%。肿瘤体积较大、有假包膜和微球尺寸较小与VL的发生独立相关。VL患者的PFS和OS比非VL患者更长，且VL与更好的PFS和OS独立相关。对于肝功能，DEB-TACE前后的肝功能指标在VL患者和非VL患者之间没有差异。此外，VL患者和非VL患者的不良事件发生率相似。
接受DEB-TACE治疗的HCC患者中，17.1%发生VL，且其与肿瘤体积较大、有假包膜、微球尺寸较小、更有利的治疗反应和更好的生存率相关。
